by Stephen F. Gorfien, GIBCO Cell Culture R&D, Invitrogen Corporation William Paul, David Judd, Lia Tescione, and David W. Jayme Cell density, longevity, and expression are the economics of cell cultures in biopharmaceutical production ? and rich growth media are the investment. Glucose and glutamine are primary energy sources for culture growth, but their associated metabolic wastes can actually harm cell cultures. Adapting cell lines to reduced levels of glucose and glutamine, then feeding the culture chemically defined nutrient supplements, increases cell viability, maximizes cell density, and increases product expression.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Filter Sizing for Process Optimization in Life Sciences Sterile Filtration
April 24th 2025Bench-scale filterability studies play a critical role in optimizing sterile filtration in biopharmaceutical manufacturing. By guiding the selection and sizing of filters, these studies help streamline processes, improve scalability, and reduce costs. Through data-driven case studies, this paper highlights how the strategic use of pre-filters and membrane materials can maximize throughput and minimize filter fouling.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.